You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
News and reporting on lung cancer.
The expanded deal will provide Med Biogene with additional markers for its LungExpress Dx test.
Rosetta Genomics, Alnylam Pharmaceuticals, Massachusetts Institute of Technology
In opening its new translational research lab, Mass General claims to be "the first and only cancer center" to attempt to molecularly profile all cancer patients that present to the facility.
Chronix Biomedical, Rosetta Genomics, National Institute of General Medical Sciences, National Center for Genome Resources, Beyond Batten Disease Research Foundation, and more ...
ASU Biodesign Institute names Alan Nelson as institute director, and Joshua LaBaer as head of institute's Piper Center for Personalized Diagnostics
During the firm's earnings call last week, CEO Amit Kumar said that the company's diagnostics services performance would be most indicative of how CombiMatrix would perform going forward.
Sequencing-Related Papers of Note, Feb. 2009
The firm published data from a study showing that the same biomarker used in its miRNA-based test for squamous lung cancer provided 96 percent sensitivity.
The hospital will use a new lab to study tumors and to try to develop individual treatments.
In its annual report, Exiqon also indicated that it would eventually seek US Food and Drug Administration approval for its miRNA diagnostics so that they could be made available to a broader range of laboratories and pathologists.
Los Angeles brought and settled a civil enforcement action against the makers of an at-home test for SARS-CoV-2, NPR reports.
The Guardian reports that Cancer Research UK is cutting its research funding by £44 million.
Technology Review examines factors affecting SARS-CoV-2 testing turnaround times.
In PNAS this week: mapping of ancient human migrations in Europe, recurrent gene fusion in breast cancer, and more.